

### **Remarks**

Claims 35, 37, and 39-88 are pending.

#### Amendments to the Claims

Claim 35 has been amended to comply with common U.S. patent practice.

Claim 36 has been canceled, as its subject matter has been incorporated into claim 43.

Claim 37 has been amended to include the subject matter of original claim 38;  
accordingly, claim 38 has been cancelled.

Claims 39-42 have been amended for consistency and to comply the claims with common U.S. patent practice.

Claim 43 has been amended to recite a process for preparing a dopant. Support for this amendment may be found in original claim 36 and throughout the specification.

New claims 44-54 have been added to comply original claim 35 with common U.S. patent practice. Support for each of these claims may be found in original claim 35.

New claims 55-64 have been amended to comply original claim 43 with common U.S. patent practice. Support for each of these amendments may be found in original claim 43.

New claims 65-74 have been added to particularly point out and distinctly claim the subject matter which Applicants regard as their invention. Claim 65 recites a process for doping an organic semi-conductor matrix material. Support for this new claim may be found in the Abstract and in paragraph [0258] of the specification. Support for claims 66-74 may be found in original claims 35 and 43.

New claims 75-88 have also been amended to particularly point out and distinctly claim the subject matter which Applicants regard as their invention. Claim 75 recites an electronic

component comprising an electronically functionally effective region, wherein the electronically effective region comprises one or more neutral metal complexes. Support for this amendment may be found in paragraph [0002] of the specification and original claims 31-33. Support for claims 76-84 may be found in original claims 35 and 43. Support for claim 85 may be found in the Abstract and in the specification at paragraph [0270]. Support for claim 86 may be found in original claim 29 and in the specification at paragraph [0257]. Support for claim 87 may be found in the specification at paragraph [0271]. Support for claim 88 may be found in the specification at paragraph [0279].

No new matter has been introduced by any of these amendments.

#### Restriction Requirement

According to Examiner, the claims of the present application contain the following groups of inventions:

Group I: claims 1-8 and 23-24, drawn to use of a metal complex as an n-dopant for producing an electronic component, wherein said complex has a central atom with a valence electron number of at least 16, or said complex is multinuclear;

Group II: claims 1-4, 9, 10, 21, and 22, drawn to the use of a metal complex as an n-dopant for producing an electronic component, wherein said complex contains a borate ligand;

Group III: claims 1-4, 11, 12, and 20, drawn to the use of a metal complex as an n-dopant for producing an electronic component, wherein the complex comprises at least one carbanion atom as a donor atom;

Group IV: claims 1-4 and 13-19, drawn to use of a metal complex as an n-dopant for producing an electronic component, wherein the complex comprises defined 5- or 6- membered heterocycles as ligands; and


Group V: claims 35-43, drawn to multinuclear complexes used as dopants, their depiction and their ligands.

Applicants elect Group V, claims 35-43, drawn to multinuclear complexes used as dopants, their depiction and their ligands.

Conclusion

Applicants respectfully submit that all claims, including those currently amended or newly added, fall within Group V. Prompt examination of all pending claims is respectfully requested.

Respectfully submitted,

A handwritten signature in cursive script, reading "Peter G. Pappas", written in dark ink.

Peter G. Pappas  
Attorney for Assignee  
Reg. No. 33,205

**Date: May 17, 2010**

SUTHERLAND ASBILL & BRENNAN LLP  
999 Peachtree Street, NE  
Atlanta, GA 30309  
Telephone: 404-853-8000  
Facsimile: 404-853-8806

**Attorney Docket No.: 17346.0088**